Y
Yuri Blaauw
Researcher at University Medical Center Groningen
Publications - 91
Citations - 2845
Yuri Blaauw is an academic researcher from University Medical Center Groningen. The author has contributed to research in topics: Atrial fibrillation & Catheter ablation. The author has an hindex of 24, co-authored 75 publications receiving 2471 citations. Previous affiliations of Yuri Blaauw include Maastricht University & University of Groningen.
Papers
More filters
Journal ArticleDOI
Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation
Jeroen M.L. Hendriks,Rianne de Wit,Harry J.G.M. Crijns,Hubertus J. M. Vrijhoef,Martin H. Prins,Ron Pisters,Laurent Pison,Yuri Blaauw,Robert G. Tieleman +8 more
TL;DR: Nurse-led care of patients with AF is superior to usual care provided by a cardiologist in terms of cardiovascular hospitalizations and cardiovascular mortality.
Journal ArticleDOI
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion
Bernhard Meier,Yuri Blaauw,Ahmed A. Khattab,Torsten Lewalter,Horst Sievert,Claudio Tondo,Michael Glikson +6 more
TL;DR: The CHADS2 score was established to assess the risk of thrombo-embolic events in patients with AF of non-valvular origin and the CHA2DS2-VASc score has recently been introduced and adopted to improve risk stratification in the low-risk group.
Journal ArticleDOI
Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation.
Laurent Pison,Mark La Meir,Jurren M. van Opstal,Yuri Blaauw,Jos G. Maessen,Harry J.G.M. Crijns +5 more
TL;DR: A combined transvenous endocardial and thoracoscopic epicardial ablation procedure for AF is feasible and safe, with a single-procedure success rate of 83% at 1 year.
Journal ArticleDOI
“Early” Class III Drugs for the Treatment of Atrial Fibrillation Efficacy and Atrial Selectivity of AVE0118 in Remodeled Atria of the Goat
TL;DR: Atrium-selective class III drugs like AVE0118 may be a promising new option for safe and effective cardioversion of AF and markedly prolongs the AERP during AF without affecting QT duration.
Journal ArticleDOI
Rationale and design of the PRAETORIAN trial: A Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter- defibrillator therapy
Louise R.A. Olde Nordkamp,Reinoud E. Knops,Gust H. Bardy,Yuri Blaauw,Lucas V.A. Boersma,Johannes S. Bos,Peter Paul H.M. Delnoy,Pascal F.H.M. van Dessel,Antoine H.G. Driessen,Joris R. de Groot,Jean Paul R. Herrman,Luc Jordaens,Kirsten M. Kooiman,Alexander H. Maass,Mathias Meine,Yuka Mizusawa,Sander G. Molhoek,Jurjen van Opstal,Jan G.P. Tijssen,Arthur A.M. Wilde +19 more
TL;DR: The PRAETORIAN trial is a randomized trial that aims to gain scientific evidence for the use of the subcutaneous ICD compared with the transvenous ICD in a population of patients with conventional ICD with respect to major ICD-related adverse events.